

**FOOD AND DRUG ADMINISTRATION (FDA)**  
**Center for Drug Evaluation and Research (CDER)**

*Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) Meeting*  
June 10, 2024

**DRAFT QUESTIONS**

---

1. **DISCUSSION:** Discuss whether the available data provide evidence of effectiveness of donanemab for the treatment of Alzheimer's disease (AD). Additionally, discuss the support for effectiveness across tau positron emission tomograph (PET) subgroups, including the no/very low tau population that was excluded from the placebo-controlled trials.
2. **VOTE:** Do the available data show that donanemab is effective for the treatment of Alzheimer's disease in the population enrolled in the clinical trials with mild cognitive impairment and mild dementia?
  - In determining your vote, if you believe there is efficacy across the entire population, or efficacy only in subset of patients (e.g., those with low/med and high Tau), please indicate that with a YES vote.
  - If your assessment is that efficacy has not been established in the overall or any subset of patients, then please indicate that with a NO vote. Explain the rationale for your vote. If you voted NO, please indicate in the discussion of your vote what additional data would be needed to support the effectiveness of donanemab for the treatment of Alzheimer's disease.
3. **DISCUSSION:** Discuss the dosing regimen used in the clinical trials that completed treatment based on reduction of amyloid plaques on PET imaging, and if there are scientific and/or clinical considerations that may factor into a decision to stop or continue dosing with donanemab if approved.
4. **DISCUSSION:** Discuss the overall benefit-risk assessment of donanemab for the treatment of Alzheimer's disease. If the available evidence supports a benefit, discuss if the risks appear to be acceptable given the observed treatment benefit and if there are subgroups of patients for whom the benefit-risk would be more or less favorable.
5. **VOTE:** Do the benefits outweigh the risks of donanemab in the treatment of AD in the population enrolled in the clinical trials with mild cognitive impairment and mild dementia?
  - Explain the rationale for your vote.
  - If you voted NO, provide recommendations for additional data or analyses that may support a conclusion that the benefits outweigh the risks.